A Microbe from Poo Suppresses Bacterial Infection

A group of gut bacteria successfully hindered recurrent Clostridium difficile infection in mice, offering alternative therapeutic strategies to antibiotics and fecal transplant.

Written bySneha Khedkar
| 3 min read
A three-dimensional closeup of blue rod-shaped bacteria.
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Bacteria in the human gut microbiome maintain a delicate balance, where beneficial bacteria keep potentially harmful microbes in check. Antibiotic treatment can disrupt this harmony, allowing pathogens like Clostridium difficile to wreak havoc, causing diarrhea, stomach cramps, and colon inflammation.1 Antibiotics also deplete the healthy microbiome, which paves the way for reinfection. Infection recurrences are difficult to treat, with one recurrence increasing the risk of repeated reinfections.2

In the past decade, researchers have shown that transplanting fecal material from healthy donors can prevent recurrent C. difficile infections.3 However, this procedure is not without risks.

“To a certain extent, a fecal transplant is almost like going to the pharmacist where they take a little bit of everything off the shelf and put it into one pill, assuming that something will probably help,” said Jordan Bisanz, a biochemist and molecular biologist at The Pennsylvania State University, in a press release. “But we don’t know 100 percent what’s in there.”

Now, in research published in Cell Host & Microbe, Bisanz and his colleagues have identified which gut bacteria can suppress C. difficile infections, laying the foundation for probiotic-based strategies as an alternative to antibiotics and fecal microbiota transplants.4

Bisanz and his team started out by investigating C. difficile’s “friends,” microbes that coexist with it, and its “enemies,” those that may suppress the bacterium. They performed a meta-analysis of previously published studies containing information about C. difficile load in people alongside gut microbiome sequencing data. With the help of machine learning, they identified 25 bacterial strains that cooccurred with C. difficile, and 37 strains that were negatively correlated with its presence.

The researchers then created a community of bacteria by coculturing the 37 strains negatively linked to C. difficile. Treating a C. difficile culture with this synthetic version of a fecal microbiota transplant (sFMT) reduced its growth. When the researchers exposed sFMT-colonized mice to C. difficile, the animals had significantly less weight loss and toxin abundance compared to control mice that received bacteria-free media.

To investigate whether a sFMT protected mice from antibiotic-induced C. difficile reinfection, the researchers treated mice with an antibiotic, infected them with C. difficile, and then treated them with another antibiotic before subjecting them to a sFMT. Compared to controls, sFMT-treated mice showed delayed infection relapse and reduced disease severity.

The researchers sought to identify the pathways through which sFMT may suppress C. difficile. Compared to mice that received human-derived fecal microbiota, those treated with sFMT exhibited higher levels of 5-aminovalerate, a metabolite produced when some microbes ferment proline, an amino acid important for C. difficile growth and virulence.5 Consistent with this, the researchers observed reduced proline levels in sFMT-colonized mice.

Removing known proline fermenters from the sFMT abolished its protective activity on C. difficile infections and resulted in severe disease symptoms in mice, establishing that proline scavenging by sFMT suppresses C. difficile. The researchers found that the bacterium Peptostreptococcus anaerobius made up a majority of the synthetic microbial community members that ferment proline.

C. difficile-exposed mice treated with P. anaerobius had reduced disease severity. The effect was comparable to what was observed in mice treated with human-derived fecal microbiota transplants, suggesting that a single bacterium could help treat C. difficile infection. Since P. anaerobius is an opportunistic pathogen, the researchers noted that other microbes with similar features could be explored as potential treatments.

“The idea was to take our understanding of basic microbiome sciences and turn it into precision-like therapies that take what we’ve learned from fecal transplants but doesn’t actually require a fecal transplant,” said Bisanz. “The goal is to develop the microbes as targeted drugs and therapies.”

Related Topics

Meet the Author

  • Sneha Khedkar

    Sneha Khedkar is an Assistant Editor at The Scientist. She has a Master’s degree in biochemistry, after which she studied the molecular mechanisms of skin stem cell migration during wound healing as a research fellow at the Institute for Stem Cell Science and Regenerative Medicine in Bangalore, India. She has previously written for Scientific American, New Scientist, and Knowable Magazine, among others.

    View Full Profile
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo
Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Twist Bio 
The Scientist Placeholder Image

Seeing and Sorting with Confidence

BD

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies